港股異動 | 四環醫藥(0460.HK)漲超5% 軒竹生物吡羅西尼獲批開展三期臨牀試驗
格隆匯11月25日丨四環醫藥(0460.HK)午後擴大漲幅,現報1.61港元,漲幅5.23%,總市值152.2億港元。公司公吿稱,集團旗下軒竹生物已收到中國國家藥品監督管理局藥品審評中心同意在研1類創新藥吡羅西尼開展三期臨牀試驗的申請。臨牀前研究結果表明,吡羅西尼具有獨特的藥代動力學特徵,能夠有效通過血腦屏障,對乳腺癌腦轉移的患者和腦癌患者預期會產生良好療效。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.